Elsevier

Drug and Alcohol Dependence

Volume 192, 1 November 2018, Pages 74-79
Drug and Alcohol Dependence

Full length article
Hepatitis C virus prevalence and estimated incidence among new injectors during the opioid epidemic in New York City, 2000–2017: Protective effects of non-injecting drug use

https://doi.org/10.1016/j.drugalcdep.2018.07.034Get rights and content

Highlights

  • Reverse transitioning was strongly associated with lower HCV seroprevalence.

  • HCV seropositivity was inversely associated with current non-injecting heroin use.

  • Injecting cocaine was associated with behavior likely to transmit HCV.

  • NYC has high rates of HCV infection among persons who began injecting since 2000.

Abstract

Objective

Assess hepatitis C virus (HCV) prevalence and incidence among person who began injecting drugs during the opioid epidemic in New York City (NYC) and identify possible new directions for reducing HCV infection among persons who inject drugs.

Methods

846 persons who began injecting drugs between 2000 and 2017 were recruited from persons entering Mount Sinai Beth Israel substance use treatment programs. A structured interview was administered and HCV antibody testing conducted. Protective effects of non-injecting drug use were examined among persons who “reversed transitioned” to non-injecting drug use and persons who used non-injected heroin in addition to injecting.

Results

Participants were 79% male, 41% White, 15% African-American, 40% Latinx, with a mean age of 35. Of those who began injecting in 2000 or later, 97 persons (11%) “reverse transitioned” back to non-injecting drug use. Reverse transitioning was strongly associated with lower HCV seroprevalence (30% versus 47% among those who continued injecting, p < 0.005). Among those who continued injecting, HCV seropositivity was inversely associated with current non-injecting heroin use (AOR = 0.72, 95%CI 0.52-0.99). HCV incidence among persons continuing to inject was estimated as 13/100 person-years. HCV seropositive persons currently injecting cocaine were particularly likely to report behavior likely to transmit HCV.

Conclusions

Similar to other locations in the US, NYC is experiencing high rates of HCV infection among persons who have begun injecting since 2000. New interventions that facilitate substitution of non-injecting for injecting drug use and that reduce transmission behavior among HCV seropositives may provide additional methods for reducing HCV transmission.

Introduction

The US is currently experiencing an opioid epidemic that has officially been declared a “public health emergency” (Gostin et al., 2017). There are multiple components to this epidemic, including excessive marketing, over-prescription and diversion of opioid analgesics, transitions from opioid analgesic use to heroin use, and transitions from oral and intranasal drug use to injecting drug use. The increase in overdose deaths, from 17,415 in 2000 to 63,632 in 2016 (Centers for Disease Control and Prevention, 2018; Hedegaard et al., 2017) may be the most dramatic indicator of the seriousness of this epidemic. Concomitant with transitions to injecting drug use, large increases in hepatitis C virus (HCV) infection have also occurred during the opioid epidemic (Des Jarlais et al., 2018; Zibbell et al., 2018). There has been considerable attention given to the opioid epidemic in suburban and rural areas of the US (Cerdá et al., 2017), but marked increases have also occurred in large urban centers.

Both HIV and HCV are transmitted through multi-person use (“sharing”) of needles and syringes for injecting illicit drugs. Syringe service programs (SSPs, primarily syringe exchange and legal over the counter sales of sterile needles and syringes), medication assisted treatment for opioid use disorders (MAT, primarily methadone and buprenorphine maintenance treatment) and anti-retroviral treatment (ART) for HIV infection have dramatically reduced HIV transmission in many areas (Des Jarlais et al., 2016a,b), but these programs have been much less effective in reducing HCV infection (Platt et al., 2017).

New York City has implemented public-health scale “combined prevention and care for HIV” among PWID and HIV incidence has been reduced to 0.01/100 PY. (Des Jarlais et al., 2016a, b) Large-scale implementation of syringe programs in New York was followed by a substantial reduction in HCV prevalence—from a near saturation level of 90% to a high but clearly less than saturation level of 70%, with an estimated HCV incidence of 18/100 person-years among persons who had begun injecting within the previous 5 years (Des Jarlais et al., 2010, 2005). Additionally, New York implemented a “Stop Hep C” program in 2004. This program included public education efforts to increase awareness of HCV, increased provision of HCV testing at programs that serve PWID, and increased referrals of HCV seropositive individuals for further evaluation and HCV treatment with the new “direct acting antivirals.” The increase in persons who have received treatment for HCV infection, however, has not been sufficient to generate a “treatment as prevention” effect for HCV. Recently, in conjunction with the NY State program to “End the HIV Epidemic,” the governor and Commissioner of Health have announced a program to “End the HCV Epidemic,” with increased funding for access to Hepatitis C medications and expanded prevention, screenings and treatment services for high risk communities (New York Governor’s Office, 2018).

Concurrent with these positive public health initiatives, New York City has been experiencing an “opioid epidemic,” with overprescribing and diversion of opioid analgesics, transitions from use of opioid analgesics to use of heroin, increased fatal opioid overdoses and transitions from non-injecting to injecting drug use (New York State Department of Health, 2018). Together these factors create conditions conducive to increased transmission of HCV.

In this report, we examine HCV seroprevalence and estimated HCV incidence among persons who began injecting drugs during the course of the “opioid epidemic” (2000–2017) in New York City. We are particularly interested in whether there have been any reductions in HCV infection, suggesting possible cumulative effects of the new interventions or increases in HCV infection, suggesting possible acceleration of the HCV/opioid injecting epidemic. We are also interested in identifying any factors that may be protective against acquiring HCV. Finally, we also consider the implications of the New York City data for addressing HCV in the opioid epidemic in other areas of the US.

Section snippets

Materials and methods

The data presented here were collected between January 2007 and December 2017 as part of a long-running study of persons entering Mount Sinai Beth Israel drug detoxification and methadone maintenance programs in New York City. The methods for this “Risk Factors” study have been previously described (Des Jarlais et al., 2009, 1989) so only a summary will be presented here. The programs serve New York City as a whole and there were no changes in the requirements for entrance into the program over

Results

Between January 2007 and December 2017, we recruited a total of 846 study participants among entrants to the Mount Sinai Beth Israel drug use treatment programs who reported beginning to inject in 2000 or later. These represented 32% of the 2687 participants who participated in our study during the data collection period and reported a history of injecting drug use. The percentage of study participants who first injected in 2000 or later among all study participants with a history of injecting

Discussion

As noted in the introduction, the Governor of New York State has recently called for an “End to HCV” in the state. Given the success of combined prevention and care controlling HIV in the state, extending public health efforts to address HCV is a laudable goal. However, this effort is being undertaken during the current opioid epidemic, which includes many persons who transition from non-injecting to injecting drug use, and who are at very high risk for acquiring HCV. The estimated incidence of

Limitations

Several limitations of this study should be noted. First, the participants were recruited from entrants into a single set system of substance use programs and are not a random sample of people who use drugs in New York City. HIV and HCV infection among participants in the Risk Factors study has tracked consistently with HIV infection data from other sources in New York City (Des Jarlais et al., 2016a,b, 2000a,b; Des Jarlais et al., 1998; Murrill et al., 2001; Thomas, 2001). We did compare our

Conclusions

Like many other areas in the US, New York City has experienced large numbers of persons beginning to inject drugs and becoming infected with HCV. Multiple interventions will be needed to control HCV infection among persons who have begun injecting during the current opioid epidemic. The New York City data suggest possible additional harm reduction strategies for reducing HCV transmission among PWID. These could include supporting “reverse transitions” from injecting back to exclusively

Role of funding sources

This work was supported through grants R01DA003574 and 5-DP1-DA039542 from the US National Institute on Drug Abuse The funding agency had no role in the design, conduct, data analysis or report preparation for the study.

Contributors

Don Des Jarlais conceived the study; Courtney McKnight managed data collection; Kamyar

Arasteh performed statistical analysis; Jonathan Feelemyer worked with data analysis and managed final editing of manuscript; Hannah Cooper, David Perlman, Susan Tross, David Barnes and Anneli Uuskula contributed to editing of the manuscript. All authors reviewed the full study and results prior to submission to the journal. All co-authors have approved the final manuscript and the revisions that are being

Conflict of interest

No conflict declared.

Acknowledgments

We would like to thank the staff at Mount Sinai Beth Israel treatment programs for their diligent work in interviewing and collecting the relevant data for this study.

References (31)

  • D.C. Des Jarlais et al.

    HIV infection during limited versus combined HIV prevention programs for IDUs in New York City: the importance of transmission behaviors

    Drug. Alcohol. Depend.

    (2010)
  • Centers for Disease Control and Prevention

    U.S. Drug Overdose Deaths Continue to Rise; Increase Fueled by Synthetic Opioids

    (2018)
  • M. Cerdá et al.

    Prescription opioid poisoning across urban and rural areas: identifying vulnerable groups and geographic areas

    Addiction

    (2017)
  • S. Deren et al.

    The Puerto Rico–New York airbridge for drug users: description and relationship to HIV risk behaviors

    J. Urban Health

    (2007)
  • D.C. Des Jarlais et al.

    HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987

    JAMA

    (1989)
  • D.C. Des Jarlais et al.

    Declining seroprevalence in a very large HIV epidemic: injecting drug users in New York City, 1991 to 1996

    Am. J. Publ. Health

    (1998)
  • D.C. Des Jarlais et al.

    HIV incidence among injecting drug users in New York City, 1992-1997: evidence for a declining epidemic

    Am. J. Publ. Health

    (2000)
  • D.C. Des Jarlais et al.

    Behavioral risk reduction in a declining HIV epidemic: injection drug users in New York City, 1990-1997

    Am. J. Publ. Health

    (2000)
  • D.C. Des Jarlais et al.

    Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001

    AIDS

    (2005)
  • D.C. Des Jarlais et al.

    Persistence and change in disparities in HIV infection among injecting drug users in New York City after large-scale syringe exchange

    Am. J. Publ. Health

    (2009)
  • D.C. Des Jarlais et al.

    HIV among drug users at Beth Israel Medical Center, New York City, the first 25 years

    Subst. Use Misuse

    (2011)
  • D.C. Des Jarlais et al.

    Consistent estimates of very low HIV incidence among people who inject drugs: New York City, 2005-2014

    Am. J. Public. Health

    (2016)
  • D.C. Des Jarlais et al.

    HIV infection among persons who inject drugs: ending old epidemics and addressing new outbreaks

    AIDS

    (2016)
  • D.C. Des Jarlais et al.

    Potential geographic "hotspots" for drug-injection related transmission of HIV and HCV and for initiation into injecting drug use in New York City, 2011-2015, with implications for the current opioid epidemic in the US

    PLoS One

    (2018)
  • B. Eckhardt et al.

    Risk factors for hepatitis C seropositivity among young people who inject drugs in New York City: implications for prevention

    PLoS One

    (2017)
  • Cited by (17)

    • Mobile low-threshold buprenorphine integrated with infectious disease services

      2022, Journal of Substance Abuse Treatment
      Citation Excerpt :

      First, the overall prevalence of HCV was 32.2%, which is lower than expected for PWUD, a population that has an estimated prevalence of 50–80% compared to 1.1% in the general population (Degenhardt et al., 2017; Denniston et al., 2014; Sulkowski & Thomas, 2005). Though we did not systematically collect data, our clinical experience suggested that Spot patients reported more intranasal drug use rather than injection drug use, which research has shown to have a lower HCV risk (Des Jarlais et al., 2018). Second, more than 70% of patients were discharged or lost to follow-up within the first three months of buprenorphine treatment, making HCV evaluation and treatment challenging.

    • Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs

      2021, International Journal of Drug Policy
      Citation Excerpt :

      Globally, an estimated 15.6 million (10.2–23.7 million) people have injected drugs in the previous year (Degenhardt et al., 2017), with two-thirds reporting greater than daily injecting (Colledge, Leung et al., 2020) and one-third reporting receptive needle-syringe sharing in the previous year (Tran et al., 2020). Given ongoing risk behaviours for transmission of blood-borne pathogens through the sharing of unsterile needles/syringes due to the inadequate supply of sterile injecting equipment globally (Des Jarlais et al., 2018; Hahn et al., 2019; Kaberg, Naver, Hammarberg, & Weiland, 2018; Morris, Shiboski et al., 2017; Puzhko et al., 2017; Valencia La Rosa et al., 2018), there is a high burden of HCV (39% prevalence, 6.1 million people infected) (Grebely, Larney et al., 2019) and HIV (18% prevalence, 2.8 million people infected) (Degenhardt et al., 2017; Larney et al., 2020) among people with recent injecting drug use. Globally, 40% of new HCV infections from 2018 to 2030 are expected to occur among people who inject drugs (Trickey et al., 2019).

    • Drug-related deaths in a population-level cohort of people living with and without hepatitis C virus in British Columbia, Canada

      2020, International Journal of Drug Policy
      Citation Excerpt :

      More than half of overdose deaths in BC were not injecting-related in 2018 (BC Coroners Service, 2018). These data underscore the need to prevent initiation of injecting drug use, to promote reversal to non-injecting use, and to minimize exposure to fentanyl to reduce DRDs (Des Jarlais et al., 2018). Indeed, increasing rates of injecting drug use, acute HCV infection, and overdose deaths signal a crisis for public health in North America and elsewhere.

    • Treating Opioid Use Disorder and Related Infectious Diseases in the Criminal Justice System

      2020, Infectious Disease Clinics of North America
      Citation Excerpt :

      Chronic HCV infection is substantially more prevalent than HIV, but screening for HCV is less common and access to treatment is currently very limited.66 The prevalence of HCV varies regionally, but estimates range between 40% and 80% among people who inject drugs.67,68 In state prison populations, HCV seroprevalence estimates range from 6% in Idaho to 40% in New Mexico.66

    • Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis

      2020, Journal of Hepatology
      Citation Excerpt :

      Globally, among the 71 million people living with HCV,1 6.1 million (8.6%) injected drugs during the previous year.2 HCV transmission continues to occur among people who have recently injected drugs.3–6 Increasing access to HCV prevention services and HCV treatment among people who inject drugs will be critical to achieving the World Health Organization goal of eliminating HCV as a major global public health threat by 2030.7

    View all citing articles on Scopus
    View full text